Van ECK Associates Corp trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 25.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,065,730 shares of the biopharmaceutical company’s stock after selling 358,011 shares during the quarter. Van ECK Associates Corp owned approximately 0.08% of Gilead Sciences worth $86,345,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in GILD. FMR LLC increased its holdings in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares in the last quarter. Macquarie Group Ltd. increased its holdings in shares of Gilead Sciences by 26.6% during the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after acquiring an additional 100,741 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares in the last quarter. Finally, Toronto Dominion Bank increased its holdings in shares of Gilead Sciences by 19.0% during the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after acquiring an additional 75,364 shares in the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences, Inc. (NASDAQ GILD) traded up $1.03 during trading hours on Wednesday, hitting $81.82. The company had a trading volume of 7,063,271 shares, compared to its average volume of 10,070,000. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $89.54. The company has a market cap of $106,850.00, a price-to-earnings ratio of 23.51, a price-to-earnings-growth ratio of -1.83 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same period in the previous year, the company posted $2.70 EPS. The firm’s revenue for the quarter was down 18.7% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences, Inc. will post 6.24 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a $0.57 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 59.77%.
GILD has been the subject of several recent research reports. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target for the company in a report on Monday, February 5th. Leerink Swann upped their price target on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a report on Thursday, October 19th. Citigroup reiterated a “buy” rating and set a $105.00 price target (up previously from $103.00) on shares of Gilead Sciences in a report on Thursday, February 8th. BMO Capital Markets upped their price target on Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a report on Thursday, February 8th. Finally, Mizuho upped their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $87.04.
In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,196,023.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 50,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now owns 3,046,766 shares in the company, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders sold a total of 418,333 shares of company stock worth $32,742,108 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Van ECK Associates Corp” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/van-eck-associates-corp-has-86-35-million-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.